Literature DB >> 2870139

Dynorphin- and enkephalin-like immunoreactivity is altered in limbic-basal ganglia regions of rat brain after repeated electroconvulsive shock.

T Kanamatsu, J F McGinty, C L Mitchell, J S Hong.   

Abstract

In an attempt to determine whether the opioid peptides derived from prodynorphin participate in the effects of electroconvulsive shock (ECS), we used radioimmunoassay and immunocytochemistry to measure dynorphin-like immunoreactivity (DN-LI) in various rat brain regions after repeated ECS treatments. Ten daily ECSs caused a significant increase in dynorphin A (1-8)-LI in most limbic-basal ganglia structures, including hypothalamus (50%), striatum (30%), and septum (30%). No significant change was found in the frontal cortex or the neurointermediate lobe of the pituitary. In contrast, 10 ECS treatments depleted DN-LI in hippocampal mossy fibers by 64%. A detailed time-course study revealed that a single shock caused a small but significant increase in hippocampal DN-LI, whereas three consecutive shocks depleted DN-LI by 30%. The maximal decrease in DN-LI was reached after six daily ECSs. The level of DN-LI in the hippocampus partly recovered, but remained lower than the control value 4, 7, and 14 d after the cessation of six daily ECSs (50, 77, and 83% of control value, respectively). In contrast with the ECS-induced depletion of hippocampal dynorphin, 10 daily ECSs caused a significant increase (40%) in (Met5)-enkephalin-LI in the hippocampus, as well as in other limbic-basal ganglia structures. Immunocytochemistry revealed that enkephalin-LI was increased in the perforant pathway, which is presynaptic to the dynorphin-containing mossy fiber pathway in the hippocampus. These observations suggest that different mechanisms may regulate these two opioid peptide systems in the hippocampus.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870139      PMCID: PMC6568463     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  9 in total

Review 1.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 2.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

3.  Chromosomal localization of the human proenkephalin and prodynorphin genes.

Authors:  M Litt; N E Buroker; S Kondoleon; J Douglass; D Liston; R Sheehy; R E Magenis
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

4.  Ultrastructural changes in granule cell somata and mossy fibers of the rat hippocampus during picrotoxin-induced convulsions.

Authors:  H Watanabe; K Mizukawa; N Otsuka
Journal:  Cell Tissue Res       Date:  1989-02       Impact factor: 5.249

Review 5.  Epilepsy as an example of neural plasticity.

Authors:  Helen E Scharfman
Journal:  Neuroscientist       Date:  2002-04       Impact factor: 7.519

6.  Elevated dynorphin in the hippocampal formation of aged rats: relation to cognitive impairment on a spatial learning task.

Authors:  H K Jiang; V V Owyang; J S Hong; M Gallagher
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

7.  Kappa opioid agonists inhibit transmitter release from guinea pig hippocampal mossy fiber synaptosomes.

Authors:  R L Gannon; D M Terrian
Journal:  Neurochem Res       Date:  1992-08       Impact factor: 3.996

8.  Differences in ME-LI and VIP-LI in discrete brain regions of seizure-naive and seizure-experienced El mice.

Authors:  T Kanamatsu; S Hirano
Journal:  Neurochem Res       Date:  1988-10       Impact factor: 3.996

Review 9.  The Opioid System in Temporal Lobe Epilepsy: Functional Role and Therapeutic Potential.

Authors:  Johannes Burtscher; Christoph Schwarzer
Journal:  Front Mol Neurosci       Date:  2017-08-07       Impact factor: 5.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.